NANOGP8 and gastric cancer: NANOGP8 has been associated with almost all malignant phenotypes of GC: it has been associated with the upregulation of GCSC markers and EMT-related genes, accumulation of β-catenin in the nucleus, enhancement of Wnt signaling, and increased gastric cancer cell drug resistance; NANOGP8 is a potential therapeutic target for gastric cancer (71).